Arthur Baudewyns

Arthur Baudewyns

Auto-generated profile, based on publicly available information

Arthur Baudewyns

Department of Urology, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2024 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
GMGeorges Mjaess
Georges Mjaess
LHLaura Haddad
Laura Haddad
TJTeddy Jabbour
Teddy Jabbour
ABArthur Baudewyns
Arthur Baudewyns
HBHenri-Alexandre Bourgeno
Henri-Alexandre Bourgeno
RDRomain Diamand
Romain Diamand

14 May 2024 in BJU International
Verified
Journal Article
Closed access
APAlexandre Peltier
Alexandre Peltier
RVRoland van Velthoven
Roland van Velthoven
ABArthur Baudewyns
Arthur Baudewyns
GAGrégoire Assenmacher
Grégoire Assenmacher
MLMarc Lemort
Marc Lemort
RDRomain Diamand
Romain Diamand

26 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
CLCharles Leplat
Charles Leplat
TJTeddy Jabbour
Teddy Jabbour
RDRomain Diamand
Romain Diamand
ABArthur Baudewyns
Arthur Baudewyns
HBHenri Alexandre Bourgeno
Henri Alexandre Bourgeno
Carlos ArtigasCarlos Artigas
Carlos Artigas
(1) Background: The European Association of Urology (EAU) biochemical recurrence (BCR) risk grouping relies on data from historical cohorts that used conventional imaging techniques. In the era of PSMA PET/CT, we compared the patterns of positivity in the two risk groups and provided insight into positivity predictive factors. (2) Methods: Data from 1185 patients who underwent 68Ga-PSMA-11PET/CT for BCR was analyzed, out of which 435 patients treated initially treated by radical prostatectomy were included in the final analysis. (3) Results: A significantly higher rate of positivity in the BCR high-risk group was observed (59% vs. 36%, p < 0.001). BCR low-risk group demonstrated more local (26% vs. 6%, p < 0.001) and oligometastatic (100% vs. 81%, p < 0.001) recurrences. The BCR risk group and PSA level at the time of PSMA PET/CT were independent predictive factors of positivity. (4) Conclusions: This study confirms that the EAU BCR risk groups have different rates of PSMA PET/CT positivity. Even with a lower rate in the BCR low-risk group, oligometastatic disease was 100% in those with distant metastases. Given the presence of discordant positivity and risk classification, integrating PSMA PET/CT positivity predictors into risk calculators for BCR might improve patient classification for subsequent treatment options. Future prospective studies are still needed to validate the above findings and assumptions.